Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
15-04-21	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
15-04-21	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
15-04-08	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
15-03-05	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
15-03-05	Wall Street closes up slightly ahead of jobs report	RE
15-03-05	AbbVie : CEO says new form of Humira could thwart generics	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-03-05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
14-06-02	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

16-01-07	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
16-01-07	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
16-01-07	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

15-03-05	Wall Street se reprend un peu dans un climat d'attente
15-03-05	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
15-03-05	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	2013-01-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.79%	-6.46%	+52.86%	+71.34%	65.83B
LONZA GROUP AG	+2.12%	+10.20%	+12.88%	+87.50%	51.87B
ARGENX SE	+6.99%	+7.85%	+6.16%	+70.97%	51.2B
IQVIA HOLDINGS INC.	+0.87%	+2.65%	+26.19%	+45.15%	43.76B
BEONE MEDICINES AG	+2.43%	+7.69%	+17.99%	+127.54%	42.09B
REVOLUTION MEDICINES, INC.	+7.33%	+2.33%	+257.04%	+589.45%	39.04B
CELLTRION, INC.	-0.40%	+9.42%	+18.44%	+59.06%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+3.84%	-4.94%	+42.35%	+8.92%	25.2B
GENMAB A/S	+2.36%	+4.98%	+30.53%	+25.63%	22.8B
Average	+2.53%	+4.32%	+51.61%	+120.62%	41.76B
Weighted average by Cap.	+2.48%	+4.18%	+50.01%	+122.52%

Employees

Sector